Clinical trials: Pulmonary Artery Hypertension
Pulmonary Hypertension
Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension
This Phase 2 study was to determine the incidence of increased serum aminotransferase concentrations (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]), as well as the overall safety and tolerability of…
- Trial name
- NCT00423592
- Testing
- ambrisentan
- Volunteers
- 36 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension, Right-Sided Heart Failure
Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot Study
Pulmonary arterial hypertension(PAH) is associated with the development of right heart failure. In the setting of heart failure, the heart shifts to increasing dependence on glucose metabolism.
- Trial name
- NCT04090866
- Testing
- PET/MRI
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Wisconsin, Madison
Pulmonary Arterial Hypertension
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
This is a 24-month, multi-center, prospective, open-label, safety evaluation in PAH subjects following transition from a stable dose of inhaled iloprost (Ventavis).
- Trial name
- NCT00741819
- Testing
- Inhaled treprostinil
- Where
- 15 sites in United States
- Volunteers
- 73 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation
- Trial name
- ADAPT (NCT03045029)
- Testing
- Oral treprostinil
- Where
- 41 sites in United States
- Volunteers
- 300 people
- Sponsor
- United Therapeutics
Hypertension, Pulmonary
A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
The safety and efficacy at 100 mg once daily for oral dose of sitaxentan sodium were demonstrated in the STRIDE clinical trial program. Sitaxentan sodium was approved in the EU, Canada and Australia.
- Trial name
- NCT01204853
- Testing
- Sitaxentan
- Where
- 2 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension
A Randomized, Placebo-Controlled, Double-blind, Dose Escalation Study to Assess Safety, Efficacy and Pharmacokinetics of GMA301 Injection in Subjects with Pulmonary Arterial Hypertension
- Trial name
- NCT04503733
- Testing
- Q4W GMA301 IV injections (300 mg), Q4W GMA301 IV injections (600 mg), Q4W GMA301 IV injections (1000 mg)
- Where
- 7 sites in United States, China
- Volunteers
- 48 people
- Sponsor
- Gmax Biopharm LLC.
Pulmonary Arterial Hypertension, Diffuse Interstitial Lung Disease
HYPID (Pulmonary Hypertension in Interstitial Lung Disease) EXTENSION
HYPID-2 study is an extension of HYPID study (NCT01443598) : HYPID-2 is also an observational and prospective study of patients with interstitial lung disease and pre capillary hypertension diagnosed by right heart sided…
- Trial name
- HYPID-2 (NCT02799771)
- Where
- France
- Volunteers
- 210 people
- Sponsor
- Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Hypertension, Pulmonary
A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).
The Study Hypothesis: Aggressive, upfront, dual therapy for treatment-naïve NYHA I/II/III PAH is superior to a traditional "step-up" approach. The study will evaluate: 1.
- Trial name
- NCT01305252
- Testing
- treprostinil inhalations, tadalafil
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Stanford University
Pulmonary Hypertension Group 1 and 4 According to Nice Classification
NIMS- New Implantable Pump in Pulmonary Arterial Hypertension, a Safety Follow up
This observational study aims to chart patients which get their prostacyclin treatment via the subcutaneous LenusPro pump. How the surgical procedure is performed and the clinical follow-up of these patients.
- Trial name
- NCT01977014
- Where
- 8 sites in Denmark, Norway and 1 more
- Volunteers
- 40 people
- Sponsor
- NordicInfu Care AB
Pulmonary Arterial Hypertension
Rehabilitation for Patients With Pulmonary Arterial Hypertension
Patients suffering from pulmonary arterial hypertension (PAH) frequently remain symptomatic despite medical therapy. Symptoms include breathlessness, poor exercise capacity and reduced quality of life.
- Trial name
- NCT00544726
- Testing
- Physical training, No training
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Rabin Medical Center
Intrahepatic Cholangiocarcinoma (Icc), Gall Bladder Cancer
Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
For advanced unresectable intrahepatic cholangiocarcinoma and gallbladder cancer, the current standard first-line treatment is a combination of chemotherapy and immunotherapy. However, the efficacy rates remain low.
- Trial name
- GOLD-HAIC (NCT06852287)
- Testing
- chemotherapy with gemcitabine and oxaliplatin; small molecure TKI lenvatinib; immune-checkpoint inhibitor toripalimab.
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pulmonary Arterial Hypertension
A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)
This study will evaluate safety, tolerability and effects on central diastolic blood pressure (cDBP) of MK-8892 given as single oral doses in healthy male participants (Panel A and B) and in male participants with…
- Trial name
- NCT01798849
- Testing
- MK-8892
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
The Effect of Slow-Paced Breathing on Patient Outcomes in Pulmonary Arterial Hypertension
This study aims to investigate the effects of slow-paced breathing (SPB) intervention applied to patients with pulmonary arterial hypertension (PAH) in the home environment on symptom management (dyspnea, fatigue, sleep quality)…
- Trial name
- NCT07232368
- Testing
- Slow-paced breathing intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Ege University
Pulmonary Hypertension, Arrhythmias, Cardiac
Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
Arrhythmias are considered a prominent phenomenon in pulmonary hypertension (PH) as the disease progresses. According primarily to retrospective studies with up to 24 hours of monitoring, supraventricular tachycardias (SVT) can…
- Conditions
- Pulmonary Hypertension, Arrhythmias, Cardiac, Heart Rate Variability, Risk Assessment
- Trial name
- ASPIRE (NCT04554160)
- Testing
- Loop recorder implantation, A smartwatch
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Pulmonary Hypertension
Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension
To assess the safety of sildenafil 20 mg TID orally given to Japanese pulmonary arterial hypertension patients (Part 1 and 2) To assess the efficacy after 12 weeks of treatment of sildenafil 20 mg TID orally given to Japanese…
- Trial name
- NCT00454207
- Testing
- sildenafil citrate (UK-92,480)
- Where
- 8 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy Adult Participants
Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults
This is a single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging from 10 μg to 20 μg.
- Trial name
- NCT06429930
- Testing
- L608 Liposomal inhalation suspension
- Where
- New Zealand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pharmosa Biopharm Inc.
Heart Failure Patients With Pulmonary Hypertension
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension
Prospective, single-arm, multicenter First in Human study to characterize the impact of pulmonary artery denervation on the quality of life in Heart Failure Patients with Pulmonary Hypertension
- Trial name
- PreVail-PH (NCT05951166)
- Testing
- Gradient Denervation System
- Where
- 2 sites in Georgia
- Volunteers
- 5 people
- Sponsor
- Gradient Denervation Technologies
Pulmonary Arterial Hypertension
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil…
- Trial name
- TRITON (NCT02558231)
- Testing
- Macitentan, Tadalafil, Selexipag
- Where
- 58 sites in United States, Australia and 13 more
- Volunteers
- 247 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension
Under placebo control, the investigators intend to evaluate the effectiveness and safety of anti-inflammatory therapy and/or targeted drug therapy for early treatment of patients with pulmonary arterial hypertension.
- Trial name
- NCT04528056
- Testing
- Sulfasalazine, Ambrisentan
- Where
- China
- Volunteers
- 80 people
- Sponsor
- RenJi Hospital
Pulmonary Hypertension, Cardiac MRI <40
Carvedilol PAH A Pilot Study of Efficacy and Safety
Estimate the effect of chronic beta-adrenergic receptor blockade with carvedilol on RV function in patients with PAH. Assess the safety and tolerability of chronic carvedilol therapy in patients with PAH
- Trial name
- NCT02120339
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Minnesota